1.Chemotherapy induced severe neutropenia.
Ji Yun HAN ; Yoo Bae AHN ; Jin Hyung KANG ; Han Rim MOON ; Young Sun HONG ; Hoon Kyo KIM ; Kyung Sik LEE ; Dong Jib KIM ; He Sook SHIN ; Hye Sun CHA
Journal of the Korean Cancer Association 1993;25(4):601-606
No abstract available.
Drug Therapy*
;
Neutropenia*
2.Clinical efficacy of thymomodulin on neutropenia induced by chemotherapy in the patients with gynecologic cancer.
Byung Ki KIM ; Chang Won KOH ; Jong Hyuk KIM ; Yong Sang SONG ; Soon Bum KANG ; Ho Pyo LEE
Journal of the Korean Cancer Association 1993;25(6):956-965
No abstract available.
Drug Therapy*
;
Humans
;
Neutropenia*
3.Efficacy of recombinant human granulocyte colony-stimulating factor(neutrogin) for chemotherapy induced neutropenia in patients with advanced lung carcinoma.
Nae Choon YOO ; Joo Hang KIM ; Yi Young LEE ; Se Kyoo KIM ; Sung Kyoo KIM ; Won Young LEE ; Bong Soo CHA ; Jin Hyuk CHOI ; Ho Young LIM ; Jae Kyung ROH ; Byung Soo KIM
Journal of the Korean Cancer Association 1993;25(2):236-246
No abstract available.
Drug Therapy*
;
Granulocytes*
;
Humans*
;
Lung*
;
Neutropenia*
4.Docetaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
Seok Bong JEON ; Byung Min AHN ; Jun Ho MUN ; Woo Jin SUNG ; Dong Hwan KIM ; Jong Gwang KIM ; Tae Bong KIM ; Ho Young JUNG ; Wan Sik YU ; Sang Kyun SOHN ; Kyu Bo LEE
Korean Journal of Medicine 2005;68(6):672-677
BACKGROUND: We evaluated the efficacy and toxicity of docetaxel plus cisplatin combination as first-line chemotherapy for advanced gastric cancer. METHODS: Patients with metastatic or recurrent gastric adenocarcinoma, performance score
Adenocarcinoma
;
Cisplatin*
;
Drug Therapy
;
Drug Therapy, Combination*
;
Febrile Neutropenia
;
Humans
;
Neutropenia
;
Stomach Neoplasms*
5.Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy.
Jae Lyun LEE ; Min Hee RYU ; Heung Moon CHANG ; Tae Won KIM ; Jeong Hwan YOOK ; Sung Tae OH ; Byung Sik KIM ; Jung Shin LEE ; Yoon Koo KANG
Cancer Research and Treatment 2005;37(4):201-207
PURPOSE: Fluoropyrimidine (F) and platinum (P) combination chemotherapy has been widely used for the first line treatment of advanced gastric cancer (AGC). Docetaxel (D) has shown promising activity in this disease. The present study retrospectively investigated the efficacy of D monotherapy as salvage chemotherapy for AGC that is failing F and P combination chemotherapy. MATERIALS AND METHODS: A total of 34 patients, fitting the eligibility criteria, were included in this study. D was administered at a dose of 75 mg/m2 IV every 3 weeks, with dexamethasone prophylaxis. Twenty-nine patients had measurable lesions. The median treatment-free interval was 38.5 days, and 91.2% of patients had progressed within 4 months of withdrawal of the first line chemotherapy. RESULTS: A total of 133 cycles of D were administered, with a median of 3.5 (1~8) cycles. From an intention-to-treat analysis, 6 patients achieved partial responses (PR), with a response rate of 20.7% (95% CI, 6.0~35.4). The duration of objective PRs in these six were 2.3+, 2.5+, 2.9, 3.0+, 6.2 and 6.8 months, respectively. Six patients showed a stable disease, but 15 showed progression. The median time to progression was 4.2 months (95% CI, 2.8~5.5), with a median overall survival since the start of D monotherapy of 8.4 months (95% CI, 5.5~11.3). Grade 3/4 neutropenia and febrile neutropenia occurred in 12.9% of patients and 3.1% of cycles. The incidence of grade 3 or worse non-hematological toxicities were as follows; peripheral sensory neuropathy 9.7%, asthenia 3.2% and allergic reaction 2.7%. CONCLUSION: Docetaxel, 75 mg/m2, is active in AGC as second-line chemotherapy after failure of prior exposure to the F and P combination chemotherapy, with a favorable toxicity profile.
Asthenia
;
Dexamethasone
;
Drug Therapy*
;
Drug Therapy, Combination*
;
Febrile Neutropenia
;
Humans
;
Hypersensitivity
;
Incidence
;
Neutropenia
;
Platinum*
;
Retrospective Studies
;
Salvage Therapy
;
Stomach Neoplasms*
6.Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer.
In Sil CHOI ; Do Youn OH ; Byoung Su KIM ; Keun Wook LEE ; Jee Hyun KIM ; Jong Seok LEE
Cancer Research and Treatment 2007;39(3):99-103
PURPOSE: We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer. MATERIALS AND METHODS: The study patients were chemotherapy-naive patients (> 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks. RESULTS: A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2~6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4~12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2. CONCLUSION: This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer.
Aged*
;
Anemia
;
Drug Therapy*
;
Febrile Neutropenia
;
Fluorouracil*
;
Humans
;
Leucovorin*
;
Neutropenia
;
Peripheral Nervous System Diseases
;
Stomach Neoplasms*
7.A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
Tak YUN ; Heung Tae KIM ; Ji Youn HAN ; Sung Jin YOON ; Hyae Young KIM ; Byung Ho NAM ; Jin Soo LEE
Cancer Research and Treatment 2016;48(2):465-472
PURPOSE: Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen. MATERIALS AND METHODS: Eligibility included histologically confirmed SCLC, one dimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and progressive disease after platinum-based chemotherapy. Treatment consisted of P (80 mg/m2) and G (1,000 mg/m2) on days 1 and 8 of each cycle of 21 days until disease progression. RESULTS: Thirty-three patients seen between December 2005 and February 2009 were selected into this study. Thirty patients (91%) had received irinotecan-platinum, and three had received etoposide-platinum. Sixteen patients (49%) had a treatment-free interval of less than 3 months. The overall response rate was 30.3% (29.4% in sensitive relapse and 31.3% in refractory relapse). The median time to progression was 12.0 weeks and median overall survival (OS) 31.0 weeks, with a 1-year OS rate of 30.3%. Toxicities were moderate and manageable with 18.2% grade (G) 4 neutropenia, 24.2% G3 thrombocytopenia, 6.1% G3 sensory neuropathy, and 3% G3 asthenia. One patient developed febrile neutropenia. CONCLUSION: Second-line paclitaxel and gemcitabine were well-tolerated and moderately active in SCLC patients previously treated with platinum-based chemotherapy.
Asthenia
;
Disease Progression
;
Drug Therapy
;
Febrile Neutropenia
;
Humans
;
Neutropenia
;
Paclitaxel*
;
Recurrence
;
Small Cell Lung Carcinoma*
;
Thrombocytopenia
8.The Effectiveness and Safety of DA-3030 ( rhG-CSF ) for Chemotherapy - induced Neutropenia: A Randomized Controlled Trial.
Dae Ho LEE ; Cheolwon SUH ; Keunchil PARK ; Tae Won KIM ; Jung Gyun KIM ; Won Seog KIM ; Won Ki KANG ; Dae Seog HEO ; Yung Jue BANG ; Noe Kyeong KIM
Journal of the Korean Cancer Association 1999;31(5):995-1002
PURPOSE: We investigated the effectiveness and safety of DA-3030 for prophylatic use in patients receiving chemotherapy for malignant disease. MATERIALS AND METHODS: Seventy cancer patients were randomized to receive chemotherapy alone (36 patients) or with DA-3030 administered (34 patients) after stratified block randomization according to chemotherapeutic regimen. DA-3030 was subcutaneously administered at the dose of 100 pg/m/day for 10 days from 24 hours after the completion of chemotherapy. RESULTS: Of the 70 enrolled patients, 62 patients were evaluable. The neutropenia (absolute neutrophil count [ANC] <1,000/mm) occurred in 9 of 32 (28.1%) of the DA-3030 group and 21 of 30 (90.0%) of the control group, giving relative risk for control group of 0.154 (95% confidence interval [CI], 0.05 to 0.45; p-0.0001). Severe neutropenia (ANC 500/mm') occurred in 4 of 32 (12.5%) of the DA-3030 group and in 20 of 30 (66.7%) of the control group (relative risk for control group of 0.316 [95% CI, 0,18 to 0.55]; p=0.0001). The mean duration of neutropenic period (+/-standard error) was 1.13+/-0.34 days in the DA-3030 group and 6.73+/-0.69 days in the control group respectively, and was significantly shorter in the DA-3030 group (p<0.0001). And, there was higher nadir ANC in the OA-3030 group than that in the control group (p=0.0001); the mean nadir ANC was 2,547+/- 343/mm and 442+/-120/mm, respectively. The DA-3030 group had significantly higher incidence of myalgia in comparison to the control group (43.8% compared with 3.3%; p=0.001). However, it was tolerable and was easily managed by conservative therapy CONCLUSION: The use of DA-3030 was effective in preventing chemotherapy-induced neutropenia.
Drug Therapy*
;
Humans
;
Incidence
;
Myalgia
;
Neutropenia*
;
Neutrophils
;
Random Allocation
9.Hepatosplenic Tuberculosis Mimicking Disseminated Candidiasis in Patients with Acute Leukemia.
Sang Young ROH ; Dong Bin KIM ; Yang Soo KIM ; Hyun Sun RHIM ; U Im CHANG ; Young Geun HYUN ; Dong Gun LEE ; Jung Hyun CHOI ; Wan Shik SHIN ; Chun Choo KIM
Korean Journal of Infectious Diseases 2000;32(6):470-473
The intensive chemotherapy for acute leukemia is often associated with profound, protracted neutropenia and increases the risk of serious infections. In general, the duration of neutropenic period correlates with the increased risk of fungal infection and multiple hepatosplenic microabscesses following neutropenic periods has been one of the major problems in patients with acute leukemia, often attributed to fungal infections such as hepatosplenic candidiasis or disseminated candidiasis. But recently we experienced two cases of hepatosplenic tuberculosis in patients with acute leukemia during or after chemotherapy following prolonged neutropenia. Tuberculosis should be considered as one of causes of hepatosplenic abscesses during prolonged neutropenia, especially in countries, where the disease is endemic.
Abscess
;
Candidiasis*
;
Drug Therapy
;
Humans
;
Leukemia*
;
Liver
;
Neutropenia
;
Spleen
;
Tuberculosis*
10.A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer.
Bong Gun SEO ; Sung Yong OH ; Dong Mee LEE ; Hyun Seung YOO ; Suee LEE ; Seong Geun KIM ; Sung Hyun KIM ; Hyuk Chan KWON ; Hyo Jin KIM
Cancer Research and Treatment 2007;39(1):6-9
PURPOSE: To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy. MATERIALS AND METHODS: Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m(2) by 3-hour infusion on day 1, and cisplatin, 60 mg/m(2) by 1 hour infusion on day 1, with the treatment repeated every 3 weeks. RESULTS: 37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade > or =2 neuropathy was observed in 6 patients (17%). CONCLUSION: The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.
Anemia
;
Cisplatin*
;
Drug Therapy
;
Drug Therapy, Combination
;
Humans
;
Neutropenia
;
Paclitaxel*
;
Salvage Therapy*
;
Stomach Neoplasms*
;
Survival Rate